Indeed, recent studies have shown that when monoclonal anti-IgE omalizumab, or the anti-IL-5 mepolizumab are added to the asthma therapy, there is a reduction in the frequency of asthma exacerbation and hospitalization and the necessity for higher doses of ICS (Stokes, 2017; Drick et al., 2018). The gene discussed is IGHE; the disease is asthma.